G E Tsai

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Glutamatergic mechanisms in schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Annu Rev Pharmacol Toxicol 42:165-79. 2002
  2. ncbi Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience (GT, McLean Hospital and Harvard Medical School, Boston, Massachusetts 02478, USA
    Biol Psychiatry 55:452-6. 2004
  3. ncbi A preliminary study of D-cycloserine treatment in Alzheimer's disease
    G E Tsai
    Geriatric Neurobehavioral Clinic, Massachusetts General Hospital, Charlestown, USA
    J Neuropsychiatry Clin Neurosci 10:224-6. 1998
  4. ncbi Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal
    G E Tsai
    Department of Psychiatry, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 155:726-32. 1998
  5. ncbi Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
    G E Tsai
    Geriatric Neurobehavoral Clinic, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Am J Psychiatry 156:467-9. 1999
  6. ncbi A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
  7. ncbi The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 174:32-8. 2004
  8. ncbi Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Joseph T Coyle
    McLean Hospital, Belmont, Massachusetts 02478, USA
    Ann N Y Acad Sci 1003:318-27. 2003
  9. ncbi Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
  10. ncbi D-serine added to clozapine for the treatment of schizophrenia
    G E Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 156:1822-5. 1999

Collaborators

Detail Information

Publications17

  1. ncbi Glutamatergic mechanisms in schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Annu Rev Pharmacol Toxicol 42:165-79. 2002
    ..Thus, hypofunction of a subpopulation of cortico-limbic NMDA receptors may participate in the pathophysiology of schizophrenia...
  2. ncbi Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience (GT, McLean Hospital and Harvard Medical School, Boston, Massachusetts 02478, USA
    Biol Psychiatry 55:452-6. 2004
    ..Glycine transporter-1 is a novel target for the pharmacotherapy to enhance N-methyl-D-aspartate function...
  3. ncbi A preliminary study of D-cycloserine treatment in Alzheimer's disease
    G E Tsai
    Geriatric Neurobehavioral Clinic, Massachusetts General Hospital, Charlestown, USA
    J Neuropsychiatry Clin Neurosci 10:224-6. 1998
    ..This double-blind crossover study of 15 mg D-cycloserine in Alzheimer's disease patients did not demonstrate clinical benefit. Higher medication dosage or long-term treatment may be required...
  4. ncbi Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal
    G E Tsai
    Department of Psychiatry, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 155:726-32. 1998
    ..Whether glutamatergic neurotransmission and oxidative stress are enhanced during ethanol withdrawal in humans is unknown...
  5. ncbi Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
    G E Tsai
    Geriatric Neurobehavoral Clinic, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Am J Psychiatry 156:467-9. 1999
    ..D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory...
  6. ncbi A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  7. ncbi The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 174:32-8. 2004
    ..Thus, there is convincing evidence that the glycine modulatory site on the NMDA receptor is a valid therapeutic target for improving cognition and associated negative symptoms in schizophrenia...
  8. ncbi Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Joseph T Coyle
    McLean Hospital, Belmont, Massachusetts 02478, USA
    Ann N Y Acad Sci 1003:318-27. 2003
    ..Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia...
  9. ncbi Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
    ..Preliminary results with an allosteric modulator of the AMPA subtype of glutamate receptor suggest enhanced cognitive functions in subjects treated with clozapine...
  10. ncbi D-serine added to clozapine for the treatment of schizophrenia
    G E Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 156:1822-5. 1999
    ..To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed...
  11. ncbi NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA
    Int Rev Neurobiol 59:491-515. 2004
  12. ncbi Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Psychiatry 51:493-7. 2002
    ....
  13. ncbi Elevated cerebrospinal fluid SNAP-25 in schizophrenia
    Peter M Thompson
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Biol Psychiatry 53:1132-7. 2003
    ..In this study, we explored SNAP-25 level and clinical variables in a new group of subjects...
  14. ncbi Gene knockout of glycine transporter 1: characterization of the behavioral phenotype
    Guochuan Tsai
    Department of Psychiatry and Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA 02178, USA
    Proc Natl Acad Sci U S A 101:8485-90. 2004
    ....
  15. ncbi Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
    Hsien-Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    Biol Psychiatry 60:645-9. 2006
    ..Clozapine possesses particular efficacy, possibly related to potentiation of NMDA-mediated neurotransmission. This may contribute to the clozapine's unique clinical efficacy and refractoriness to the addition of NMDA-enhancing agents...
  16. ncbi Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia
    Pao Yen Lin
    Department of Psychiatry, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
    Schizophr Res 71:353-60. 2004
    ..These results suggested that the variations at the NT3 and the CNTF genes do not influence the schizophrenia risk, but a role in the susceptibility of subgroups of the patients cannot be excluded...
  17. ncbi Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice
    Marzia Martina
    Departments of Cellular and Molecular Medicine, and Psychiatry, University of Ottawa, Ottawa, ON, Canada
    J Physiol 563:777-93. 2005
    ..Overall, these findings highlight the importance of GlyT1 in regulating glutamatergic neurotransmission...